OvaRex MAb-B43.13

MAb-B43.13 · Unither Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for OvaRex MAb-B43.13, covering 2007-12-18 to 2007-12-18. Get the full timeline:

Most recent: Clinical Trial Update: Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma [Phase 2]

See pricing